Tibion Corp.
This article was originally published in Start Up
Executive Summary
The designs and materials may be more sophisticated, but orthotic devices today play the same role that they always have: to passively stabilize damaged muscles or limbs. Technical advances in software, mechanical and electrical engineering are driving the development of active orthotics--devices that not only support, but also assist and augment muscle strength. Tibion intends to be one of the first to market with wearable, sensor-driven orthotics designed to restore mobility to patients who have lost muscle function due to disease, injury or aging. In addition to improving the quality of life for these patients, its devices can also provide active resistance to strengthen underyling muscle, leading to shorter recovery times and improved outcomes.
You may also be interested in...
Myomo Inc.
Myomo is capitalizing on the growing tide of scientific evidence that patients have the ability to recover motor function following neurological trauma, such as stroke. The first product from its NeuroRobotics platform is the e100 NeuroRobotic System, a lightweight robotic brace that slides onto the arm and helps improve the patient's mobility by enabling him to initiate and control movement of partially paralyzed muscles by using his own biological signals.
Start-Up Previews (4/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.
Start-Up Previews (4/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.